Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases

Journal of Gastrointestinal Oncology

Volumn 6, Issue 6, 2015, Pages 594-604

  Kennedy, Andrew S ^a,b   Ball, David S ^c   Cohen, Steven J ^c   Cohn, Michael ^d   Coldwell, Douglas M ^e   Drooz, Alain ^f   Ehrenwald, Eduardo ^g   Kanani, Samir ^h   Nutting, Charles W ⁱ   Moeslein, Fred M ^j   Putnam, Samuel G ^c   Rose, Steven C ^k   Savin, Michael A ^l   Schirm, Sabine ^a   Sharma, Navesh K ^m   Wang, Eric A ⁿ  

^a Cancer Centers of North Carolina   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d Radiology Associates   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f Fairfax Radiological Consultants   (United States)

^g ABBOTT NORTHWESTERN HOSPITAL   (United States)

^h INOVA FAIRFAX HOSPITAL   (United States)

ⁱ Radiology Imaging Associates   (United States)

^j UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^l OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁿ Charlotte Radiology PA   (United States)

more..

Author keywords

90Y microsphere; Colorectal cancer (CRC); Hepatic imaging; Radioembolization (RE)

Indexed keywords

MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; EDEMA; FEMALE; FOLLOW UP; HEPATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; RADIATION DOSE; RADIOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR NECROSIS; VERY ELDERLY;

EID: 84995773260     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2015.082     Document Type: Article

References (58)

1. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9.
2. McMillan D.C., McArdle C.S. Epidemiology of colorectal liver metastases. Surg Oncol 2007;16:3-5.
3. Young A.L., Adair R., Culverwell A., et al. Variation in referral practice for patients with colorectal cancer liver metastases. Br J Surg 2013;100:1627-32.
4. Kennedy A.S., Nutting C., Coldwell D., et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552-63.
5. Cosimelli M., Golfieri R., Cagol P.P., et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010;103:324-31.
6. Hendlisz A., Vanden Eynde M., Peeters M., et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28:3687-94.
7. Van Hazel G.A., Pavlakis N., Goldstein D., et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009;27:4089-95.
8. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007;25:1099-106.
9. Van Hazel G., Blackwell A., Anderson J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85.
10. Kosmider S., Tan T.H., Yip D., et al. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011;22:780-6.
11. Lim L., Gibbs P., Yip D., et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIRspheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 2005;5:132.
12. Gulec S.A., Pennington K., Wheeler J., et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: An in vivo double-arm-controlled phase II trial. Am J Clin Oncol 2013;36:455-60.
13. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-23.
14. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24:3245-51.
15. Gonzalez-Guindalini F.D., Botelho M.P., Harmath C.B., et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 2013;33:1781-800.
16. Hipps D., Ausania F., Manas D.M., et al. Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response? HPB Surg 2013;2013:570808.
17. Kennedy A.S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 2006;65:412-25.
18. Kennedy A.S., Ball D., Steven J., et al. Safety and efficacy of resin 90Y-microspheres in 548 patients with colorectal liver metastases progressing on systemic chemotherapy. ASCO Gastrointestinal Cancers Symposium. San Francisco, California, USA, 2013:Abs 264.
19. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
21. Coldwell D.M., Sewell P.E. The expanding role of interventional radiology in the supportive care of the oncology patient: From diagnosis to therapy. Semin Oncol 2005;32:169-73.
22. Kennedy A., Nag S., Salem R., et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68:13-23.
23. Salem R., Thurston K.G., Carr B.I., et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13:S223-9.
24. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711-20.
25. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
27. Miller F.H., Keppke A.L., Reddy D., et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007;188:776-83.
28. Atassi B., Bangash A.K., Bahrani A., et al. Multimodality imaging following 90Y radioembolization: A comprehensive review and pictorial essay. Radiographics 2008;28:81-99.
29. Guo Y., Yaghmai V., Salem R., et al. Imaging tumor response following liver-directed intra-arterial therapy. Abdom Imaging 2013;38:1286-99.
30. Kalva S.P., Rana R.S., Liu R., et al. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer. Am J Clin Oncol 2014. [Epub ahead of print].
31. Saxena A., Meteling B., Kapoor J., et al. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol 2015;22:794-802.
32. Sofocleous C.T., Garcia A.R., Pandit-Taskar N., et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer 2014;13:27-36.
33. Benson A.B.3rd., Geschwind J.F., Mulcahy M.F., et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 2013;49:3122-30.
34. Smits M.L., Vanden Hoven A.F., Rosenbaum C.E., et al. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases. PLoS One 2013;8:e69448.
35. Seidensticker R., Denecke T., Kraus P., et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012;35:1066-73.
36. Martin L.K., Cucci A., Wei L., et al. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer 2012;11:195-9.
37. Zerizer I., Al-Nahhas A., Towey D., et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: Comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 2012;39:1391-9.
38. Nace G.W., Steel J.L., Amesur N., et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: A single institution experience. Int J Surg Oncol 2011;2011:571261.
39. Cianni R., Urigo C., Notarianni E., et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 2009;32:1179-86.
40. Jakobs T.F., Hoffmann R.T., Dehm K., et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008;19:1187-95.
41. Chua T.C., Bester L., Saxena A., et al. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2011;137:865-73.
42. Mulcahy M.F., Lewandowski R.J., Ibrahim S.M., et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009;115:1849-58.
43. Stubbs R.S., O'Brien I., Correia M.M. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: Single-centre experience with 100 patients. ANZ J Surg 2006;76:696-703.
44. Lewandowski R.J., Thurston K.G., Goin J.E., et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16:1641-51.
45. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009;20:1842-7.
46. Chalian H., Töre H.G., Horowitz J.M., et al. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics 2011;31:2093-105.
47. Duke E., Deng J., Ibrahim S.M., et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 2010;21:515-21.
48. Kamel I.R., Reyes D.K., Liapi E., et al. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18:49-56.
49. Rhee T.K., Naik N.K., Deng J., et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: Comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008;19:1180-6.
50. Dudeck O., Zeile M., Wybranski C., et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 2010;20:2699-706.
51. Wybranski C., Zeile M., Löwenthal D., et al. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-doserate brachytherapy of colorectal liver metastases. Radiat Oncol 2011;6:43.
52. Löwenthal D., Zeile M., Lim W.Y., et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: Comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011;21:832-40.
53. Tajima T., Akahane M., Takao H., et al. Detection of liver metastasis: Is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases? Jpn J Radiol 2012;30:648-58.
54. Szyszko T., Al-Nahhas A., Canelo R., et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomography. Nucl Med Commun 2007;28:15-20.
55. Tochetto S.M., Töre H.G., Chalian H., et al. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response. AJR Am J Roentgenol 2012;198:1093-9.
56. Dezarn W.A., Cessna J.T., DeWerd L.A., et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 2011;38:4824-45.
57. Fendler W.P., Philippe Tiega D.B., Ilhan H., et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med 2013;54:1202-8.
58. Morsbach F., Pfammatter T., Reiner C.S., et al. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases. Invest Radiol 2013;48:787-94.